Pharma, Biotech and Generics Industry News | The Pharmaletter
WEB6 days ago · Generics. 9 September 2024 A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 5 September 2024 Amid an explosion in investment and development milestones seen over the past decade ...
Login - The Pharmaletter
WEB5 days ago · The Pharma Letter. 39-43 Putney High Street, Putney London, SW15 1SP United Kingdom
2023 Pharma Outlook – trends shaping the year ahead
WEB6 January 2023. Professional services company PwC has released a new report, PwC’s Next In Pharma and Life Sciences 2023 Report. This highlights the outlook for the pharmaceutical and life sciences industry, and the biggest c-suite agenda topics that will shape 2023. Amid high inflation, talent shortages, rising capital costs, blockbuster ...
Pharmaceutical Industry News | The Pharmaletter
WEBAug 20, 2024 · MHRA finds no evidence to support a link between GLP-1s and suicidal thoughts. MHRA has concluded that the available evidence does not establish a causal relationship between glucagon-like peptide-1 (GLP-1) receptor agonists and suicidal behavior, suicidal ideation, self-injury and depression. 4 September 2024. 12 …
The FDA accelerated drug approval program: benefits and …
WEBSep 24, 2021 · The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious diseases.1 However, recent controversies regarding AAP drugs have brought the program under severe scrutiny. We discuss the pros and cons of the program and ...
Pharma and Biotech News | The Pharmaletter
WEB4 days ago · Research shows migraine market to reach $16.4 billion by 2033. The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024. Biotechnology.
LEO Pharma in first microbiome-based deal
WEBBiotechnology. 12 April 2018. Privately-held dermatology specialist LEO Pharma has made its first investment in microbiome technology. The Danish company will invest $500,000 in Naked Biome, a San Francisco-based translational microbiome company developing live biologic therapies to treat skin disease, with a current focus in acne.
Ribon Therapeutics inks pre-clinical CD38 program deal with …
WEB30 November 2022. Cambridge, USA-based biotech Ribon Therapeutics has entered into an agreement on the acquisition of its CD38 program with Germany’s family-owned pharma major Boehringer Ingelheim. This includes a small molecule inhibitor designed to modulate intra- and extracellular CD38 activity, potentially restoring immune function in ...
About The Pharma Letter | The Pharmaletter
WEB5 days ago · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world providing insight on local markets.
Available evidence does not support GLP-1 receptor agonists link …
WEBOct 27, 2023 · This article is accessible to registered users, to continue reading please register for free.. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the …